This white paper, based on two live
web panels from October 6 and December 10, 2015, discusses what’s exciting in immuno-oncology drug development versus what is not popular in licensing, and why.
For the live events, biotech licensing and pharmaceutical business development consultant Linda Pullan was joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm.
The panelists discussed why immuno-oncology is so hot, if it is too late to get into PD1 and other checkpoint inhibitors, how they judge immuno-oncology combinations, if CAR T can go into solid tumors, the impact of business models on cell therapy, winning strategies for deals in immuno-oncology licensing, cell recruitment, innate immunity, licensing criteria, biomarkers, deal terms, and more.
If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to read these perspectives.
the white paper
Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.